Research article · 3 Mar 2025
Research articlePublished 13 Jun 2016
A Retrospective Evaluation of Pulmonary Vasodilator Monotherapy and Sequential Combination Therapy in Thai Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: This retrospective study evaluated the outcomes of Thai patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) treated with initial monotherapy and subsequent sequential combination therapy upon clinical worsening. Methods: Patients aged 1–65 years with a diagnosis of PAH-CHD who received initial monotherapy at Siriraj Hospital, Bangkok, Thailand, from January 01, 2013 to December 31, 2014 were included in this retrospective analysis. Clinical worsening was assessed using the 6-minute walking distance (6MWD) test. Results: A total of 88 patients who met study inclusion criteria had received initial monotherapy with either bosentan (n=6), sildenafil (n=47) or beraprost (n=35). Forty-four (50%) of these patients experienced a predefined clinical worsening event within 12 months of commencing treatment. Patients who received initial bosentan monotherapy were significantly less likely to experience clinical worsening compared with sildenafil and beraprost recipients at 12 months (16.7% vs. 38.3% and 71.4%, respectively; p=0.039), and 24 months (16.7% vs 61.7% and 77.1%, respectively; p=0.007). Thirty-three patients who failed initial monotherapy were subsequently prescribed sequential combination therapy. The 6MWD (mean ± standard error) increased significantly after commencement of sequential combination therapy from 208.9 ± 67.2 m before the addition of the second drug to 285.5 ± 92.1 m at 1 month (p=0.09) and 326.3 ± 62.7 m at 3 months (p=0.001). Conclusion: This retrospective analysis showed that PAHCHD patients who received initial bosentan monotherapy were significantly less likely to experience clinical worsening over 24 months than those who received sildenafil or beraprost. Sequential combination therapy initiated upon clinical worsening significantly improved 6MWD at 3 months. The findings support the use of sequential combination therapy in patients with PAH-CHD who fail initial monotherapy.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in International Journal of Cardiovascular Research.
Case report · 21 Feb 2025
Double Trouble-Lignocaine Induced Complete Heart Block in QRBBB-ACS
Research article · 16 Jan 2025
Urinary Sodium Excretion and Frequently Consumed High Sodium Foods by Civil Servants in South West Nigeria
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Cardiovascular Research
- SubjectCardiology
- BylineArticles whose byline prints “Durongpisitkul K”
- BylineArticles whose byline prints “Plearntammakun P”
- BylineArticles whose byline prints “Vijarsorn C”
